CD276 and prostate cancer: Some FDA approved drugs targeting B7-H3 such as 131I Omburtamab for neuroblastoma, Enoblituzumab for prostate cancer, and GSK5764227 (HS-20093) for small-cell lung cancer, highlights the progress in this area.